Developer docs
API playgroundTry for free, no card

Search company profiles

ENEA Tech e Biomedical

Full company profile

uuid0006dem

Namestring
ENEA Tech e Biomedical
Legal namestring
Fondazione ENEA Tech e Biomedical
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Fondazione ENEA Tech e Biomedical is an Italian private foundation supervised by the Ministry of Enterprises and Made in Italy (MIMIT) and the Ministry of Health, headquartered in Rome. It operates as a state-backed technology transfer and biomedical investment vehicle, deploying capital through two principal programs: the Technology Transfer Fund (covering green/circular economy, IT, agri-tech, and deep tech) and the Biomedical Industrial Research and Development Fund (covering drugs, vaccines, diagnostics, and medical devices). Its functional role is to bridge Italian academic and clinical biomedical research with industrial commercialization, funding startups, spin-offs, and SMEs through equity investments, co-investments (notably with CDP Venture Capital), and non-repayable grants up to €20 million per project.

The foundation's portfolio reflects a deliberate diversification across high-value biomedical subsectors. It wholly owns Holostem Terapie Avanzate (cell and gene therapy for rare diseases), led a €7.15 million round into Cellply (automated QC for advanced therapy medicinal products), participated in WISE S.p.A.'s €30 million Series D (implantable neural electrodes and brain-computer interfaces) and BionIT Labs' €5.5 million round (bionic prosthetics), and co-acquired a stake in Oversonic Robotics alongside STMicroelectronics (cognitive humanoid robotics). Geographic activity is anchored in Italy with explicit transatlantic outreach toward the US and Latin America.

The foundation does not sell products or services; its revenue model is the deployment of state-allocated and partner capital into portfolio companies. Governance is exercised through a board including figures such as Giovanni Tria, Sergio Abrignani, and Paolo Bonaretti, with compliance functions (RPCT, RASA) formalized. Its strategic posture combines financial returns with national-policy objectives around Italy's life sciences sovereignty, biotech industrial development, and attraction of foreign biomedical investment.

Short descriptiontext

ENEA Tech e Biomedical is an Italian government-supervised private foundation that invests in technology transfer and biomedical R&D, deploying grants and equity into Italian startups, spin-offs, and SMEs across cell and gene therapy, medical devices, neuromodulation, and deep tech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRome, Italy
HQ citystring
Rome
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical research funding, technology transfer investment, life sciences venture capital, biomedical innovation grants, industrial R&D funding
Industry2 codes
PRIMARYFSANAJAI
Healthcare Access & Life Sciences Impact Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Health and Welfare Funds52512
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Investment Advice6282
  • Services-Misc Health & Allied Services, Nec8090
Product category
Biomedical Research Investment
Revenue model1 record
1Technology Transfer Investments
TypeManaged Services
Description

The foundation supports investments in technology transfer, biomedical research, and industrial development through participation in startups, spin-offs, and SMEs with high growth potential. It operates through the Technology Transfer Fund and the Biomedical Industrial Development Fund.

eneatechbiomedical.it
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Fondazione ENEA Tech e Biomedical is an Italian private foundation that operates investment funds (the Technology Transfer Fund and the Biomedical Industrial Research and Development Fund) to support startups, spin-offs, and SMEs in the biomedical sector. It provides equity investments, co-investments, and non-repayable contributions for industrial research and experimental development projects in pharmaceuticals, medical devices, diagnostics, cell and gene therapy, and regenerative medicine, while also publishing public calls for proposals offering contributions up to EUR 20 million per project.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ENEA Tech e Biomedical is a private Italian foundation supervised by the Ministry of Enterprises and Made in Italy and Ministry of Health. It is not a product company but rather an investment and funding vehicle focused on technology transfer, biomedical research, and industrial development in Italy. The foundation supports startups, spin-offs, and SMEs operating in green and circular economy, Information Technology, agri-tech, and deep tech sectors through its Technology Transfer Fund, as well as industrial projects for drugs, vaccines, diagnostic products, and medical devices through its Biomedical Fund. The foundation also publishes public calls for proposals offering non-repayable contributions (up to €20 million per project with a minimum project value of €20 million) for industrial research and experimental development projects in the biomedical sector, drawing from a €40 million Biomedical Fund. ENEA Tech e Biomedical does not develop or sell its own commercial products or software platforms.

Product and service1 record
1Technology Transfer Fund (Fondo Trasferimento Tecnologico)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1CellSeed Inc.
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

CellSeed Inc. is identified as a key company actively involved alongside Foundation ENEA Tech Biomedical in developing and commercializing advanced regenerative medicine technologies in the cell sheet-based gene therapy market in Europe.

globenewswire.com
2Ministry of Enterprises and Made in Italy
Strategic tierGovernanceTypeOthers
Description

The foundation is supervised by Italy's Ministry of Enterprises and Made in Italy (MIMIT) and Ministry of Health, which provide institutional oversight and strategic direction for the foundation's investment activities.

eneatechbiomedical.it
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Panakès Partners
TypeDirect peer
Description

Italian/European life sciences venture capital firm investing in early-stage medical devices, diagnostics, and therapeutics. Closely comparable in its focus on biomedical startups across Italy and Europe with a similar check size and stage.

TypeBroad incumbent
Description

EU-level investment vehicle backing breakthrough and deep tech innovation, with a large life sciences allocation. Overlaps with ENEA Tech's portfolio in early-stage biomedical and deep tech, though at EU rather than Italian national level.

TypeBroad incumbent
Description

Pan-European fund-of-funds manager with significant life sciences and impact mandates. Operates at greater scale and broader mandate, but overlaps as a public-sector investor in European biomedical innovation.

TypeDirect peer
Description

Italian state-backed venture capital arm of Cassa Depositi e Prestiti. Directly co-invests with ENEA Tech in biomedical rounds (Cellply, BionIT Labs), operates comparable Italian-focused technology transfer funds, and shares the same national mandate to industrialize Italian R&D.

TypeDirect peer
Description

European venture capital firm dedicated to early-stage life sciences, including therapeutics, medtech, and diagnostics. Comparable as a specialist biomedical investor in the same deal universe as ENEA Tech's portfolio.

TypeOthers
Description

Italian life sciences research foundation funded by the government, with which ENEA Tech has co-organized events. Adjacent as a publicly funded life sciences institution rather than a direct investment competitor.

7Invitalia
TypeDirect peer
Description

Italian national agency for enterprise and investment promotion, operating venture and growth capital vehicles for Italian SMEs and startups. Comparable as a state-backed deployer of patient capital into Italian innovation, with overlapping industrial policy objectives.

TypeDirect peer
Description

Italian early-stage technology VC investing in deep tech and life sciences. Co-invested with ENEA Tech in WISE's Series D and pursues a similar thesis around technology transfer from Italian research institutions to commercial ventures.

TypeEmerging player
Description

Largest Italian business angel network investing in innovative Italian startups, including in life sciences. Adjacent early-stage capital provider that often co-invests with institutional funds in the same deals.

TypeDirect peer
Description

Italian venture capital manager with a deep tech and life sciences focus. Co-invested alongside ENEA Tech in WISE's €30M Series D and operates a comparable Italian early-stage investment thesis, making it a direct co-investor peer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment16 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ENEA Tech e Biomedical

Biomedical Research Investmenteneatechbiomedical.it

ENEA Tech e Biomedical is an Italian government-supervised private foundation that invests in technology transfer and biomedical R&D, deploying grants and equity into Italian startups, spin-offs, and SMEs across cell and gene therapy, medical devices, neuromodulation, and deep tech.

What ENEA Tech e Biomedical does

Fondazione ENEA Tech e Biomedical is an Italian private foundation supervised by the Ministry of Enterprises and Made in Italy (MIMIT) and the Ministry of Health, headquartered in Rome. It operates as a state-backed technology transfer and biomedical investment vehicle, deploying capital through two principal programs: the Technology Transfer Fund (covering green/circular economy, IT, agri-tech, and deep tech) and the Biomedical Industrial Research and Development Fund (covering drugs, vaccines, diagnostics, and medical devices). Its functional role is to bridge Italian academic and clinical biomedical research with industrial commercialization, funding startups, spin-offs, and SMEs through equity investments, co-investments (notably with CDP Venture Capital), and non-repayable grants up to €20 million per project.

The foundation's portfolio reflects a deliberate diversification across high-value biomedical subsectors. It wholly owns Holostem Terapie Avanzate (cell and gene therapy for rare diseases), led a €7.15 million round into Cellply (automated QC for advanced therapy medicinal products), participated in WISE S.p.A.'s €30 million Series D (implantable neural electrodes and brain-computer interfaces) and BionIT Labs' €5.5 million round (bionic prosthetics), and co-acquired a stake in Oversonic Robotics alongside STMicroelectronics (cognitive humanoid robotics). Geographic activity is anchored in Italy with explicit transatlantic outreach toward the US and Latin America.

The foundation does not sell products or services; its revenue model is the deployment of state-allocated and partner capital into portfolio companies. Governance is exercised through a board including figures such as Giovanni Tria, Sergio Abrignani, and Paolo Bonaretti, with compliance functions (RPCT, RASA) formalized. Its strategic posture combines financial returns with national-policy objectives around Italy's life sciences sovereignty, biotech industrial development, and attraction of foreign biomedical investment.

ENEA Tech e Biomedical firmographics

Firmographics
Name
ENEA Tech e Biomedical
Legal name
Fondazione ENEA Tech e Biomedical
Website
https://eneatechbiomedical.it
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
ENEA Tech e Biomedical is an Italian government-supervised private foundation that invests in technology transfer and biomedical R&D, deploying grants and equity into Italian startups, spin-offs, and SMEs across cell and gene therapy, medical devices, neuromodulation, and deep tech.
Ownership category
akta.pro rank

ENEA Tech e Biomedical industry classification

Industry
Product category
Biomedical Research Investment
NAICS
Health and Welfare Funds (52512), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Investment Advice (6282), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYFSANAJAI
Healthcare Access & Life Sciences Impact Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Biomedical research funding
  • Technology transfer investment
  • Life sciences venture capital
  • Biomedical innovation grants
  • Industrial R&D funding

Where ENEA Tech e Biomedical is headquartered

Location

Headquarters

HQ city
Rome
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

ENEA Tech e Biomedical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Revenue model

  1. Technology Transfer Investments: The foundation supports investments in technology transfer, biomedical research, and industrial development through participation in startups, spin-offs, and SMEs with high growth potential. It operates through the Technology Transfer Fund and the Biomedical Industrial Development Fund.

Marketing channels4 records

ENEA Tech e Biomedical product offering

Product offering

Core offering

Fondazione ENEA Tech e Biomedical is an Italian private foundation that operates investment funds (the Technology Transfer Fund and the Biomedical Industrial Research and Development Fund) to support startups, spin-offs, and SMEs in the biomedical sector. It provides equity investments, co-investments, and non-repayable contributions for industrial research and experimental development projects in pharmaceuticals, medical devices, diagnostics, cell and gene therapy, and regenerative medicine, while also publishing public calls for proposals offering contributions up to EUR 20 million per project.

Product overview

ENEA Tech e Biomedical is a private Italian foundation supervised by the Ministry of Enterprises and Made in Italy and Ministry of Health. It is not a product company but rather an investment and funding vehicle focused on technology transfer, biomedical research, and industrial development in Italy. The foundation supports startups, spin-offs, and SMEs operating in green and circular economy, Information Technology, agri-tech, and deep tech sectors through its Technology Transfer Fund, as well as industrial projects for drugs, vaccines, diagnostic products, and medical devices through its Biomedical Fund. The foundation also publishes public calls for proposals offering non-repayable contributions (up to €20 million per project with a minimum project value of €20 million) for industrial research and experimental development projects in the biomedical sector, drawing from a €40 million Biomedical Fund. ENEA Tech e Biomedical does not develop or sell its own commercial products or software platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Technology Transfer Fund (Fondo Trasferimento Tecnologico)

Companies that use ENEA Tech e Biomedical

Customer profile

Segments1 record

Ideal customer profiles1 record

ENEA Tech e Biomedical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ENEA Tech e Biomedical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered strategic and governance.

  • CellSeed Inc.strategicStrategic or Co-development PartnerCellSeed Inc. is identified as a key company actively involved alongside Foundation ENEA Tech Biomedical in developing and commercializing advanced regenerative medicine technologies in the cell sheet-based gene therapy market in Europe.
  • Ministry of Enterprises and Made in ItalygovernanceOthersThe foundation is supervised by Italy's Ministry of Enterprises and Made in Italy (MIMIT) and Ministry of Health, which provide institutional oversight and strategic direction for the foundation's investment activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

ENEA Tech e Biomedical competitors and assessment

Company assessment

Direct peers

  • Panakès Partners: Italian/European life sciences venture capital firm investing in early-stage medical devices, diagnostics, and therapeutics. Closely comparable in its focus on biomedical startups across Italy and Europe with a similar check size and stage.
  • CDP Venture Capital: Italian state-backed venture capital arm of Cassa Depositi e Prestiti. Directly co-invests with ENEA Tech in biomedical rounds (Cellply, BionIT Labs), operates comparable Italian-focused technology transfer funds, and shares the same national mandate to industrialize Italian R&D.
  • BioGeneration Ventures: European venture capital firm dedicated to early-stage life sciences, including therapeutics, medtech, and diagnostics. Comparable as a specialist biomedical investor in the same deal universe as ENEA Tech's portfolio.
  • Invitalia: Italian national agency for enterprise and investment promotion, operating venture and growth capital vehicles for Italian SMEs and startups. Comparable as a state-backed deployer of patient capital into Italian innovation, with overlapping industrial policy objectives.
  • Eureka! Venture SGR: Italian early-stage technology VC investing in deep tech and life sciences. Co-invested with ENEA Tech in WISE's Series D and pursues a similar thesis around technology transfer from Italian research institutions to commercial ventures.
  • Indaco Ventures SGR: Italian venture capital manager with a deep tech and life sciences focus. Co-invested alongside ENEA Tech in WISE's €30M Series D and operates a comparable Italian early-stage investment thesis, making it a direct co-investor peer.

Broad incumbents

  • EIC Fund (European Innovation Council): EU-level investment vehicle backing breakthrough and deep tech innovation, with a large life sciences allocation. Overlaps with ENEA Tech's portfolio in early-stage biomedical and deep tech, though at EU rather than Italian national level.
  • European Investment Fund (EIF): Pan-European fund-of-funds manager with significant life sciences and impact mandates. Operates at greater scale and broader mandate, but overlaps as a public-sector investor in European biomedical innovation.

Others

  • Human Technopole: Italian life sciences research foundation funded by the government, with which ENEA Tech has co-organized events. Adjacent as a publicly funded life sciences institution rather than a direct investment competitor.

Emerging players

  • Italian Angels for Growth (IAG): Largest Italian business angel network investing in innovative Italian startups, including in life sciences. Adjacent early-stage capital provider that often co-invests with institutional funds in the same deals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

ENEA Tech e Biomedical social profiles

Digital presence

ENEA Tech e Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ENEA Tech e Biomedical leadership team

Management profile

Number of profiles

Profiles3 records

ENEA Tech e Biomedical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ENEA Tech e Biomedical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ENEA Tech e Biomedical M&A and investment

M&A and investment

M&A1 record

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENEA Tech e Biomedical

What does ENEA Tech e Biomedical do?

Fondazione ENEA Tech e Biomedical is an Italian private foundation that operates investment funds (the Technology Transfer Fund and the Biomedical Industrial Research and Development Fund) to support startups, spin-offs, and SMEs in the biomedical sector. It provides equity investments, co-investments, and non-repayable contributions for industrial research and experimental development projects in pharmaceuticals, medical devices, diagnostics, cell and gene therapy, and regenerative medicine, while also publishing public calls for proposals offering contributions up to EUR 20 million per project.

Is ENEA Tech e Biomedical a public or private company?

ENEA Tech e Biomedical is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was ENEA Tech e Biomedical founded?

ENEA Tech e Biomedical was founded in -1. It employs 11 to 50 people.

Where is ENEA Tech e Biomedical based?

ENEA Tech e Biomedical is headquartered in Rome, Italy, in the Europe region.

How does ENEA Tech e Biomedical make money?

One revenue line is on record: technology Transfer Investments.

Who are ENEA Tech e Biomedical's main competitors?

Direct peers on record are Panakès Partners, CDP Venture Capital, BioGeneration Ventures, Invitalia, Eureka! Venture SGR and Indaco Ventures SGR. Broad incumbents are EIC Fund (European Innovation Council) and European Investment Fund (EIF). Human Technopole is listed as an others. Italian Angels for Growth (IAG) is listed as an emerging player.

Does ENEA Tech e Biomedical have an API?

No public API is recorded for ENEA Tech e Biomedical.

What industry is ENEA Tech e Biomedical in?

ENEA Tech e Biomedical's product category is Biomedical Research Investment. Its primary akta.pro industry code is FSANAJAI, Healthcare Access & Life Sciences Impact Funds, with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 52512 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Il Sole 24 ORERehabilitation of the highest standard: the future of Santa Lucia, combining growth, research and careOn July 1, LIFE – Istituto di Ricerca e Cura began the process of safeguarding and revitalizing Santa Lucia IRCCS, one of Italy's leading centers of excellence in neuroscience and neurorehabilitation, through a complex acquisition involving collaboration between the Lazio Region, INAIL, and ENEA Tech and Biomedical Foundation. The new accreditation system approved by the Lazio Regional Government increased bed capacity from 325 to 365 and outpatient physiotherapy capacity from approximately 300 to over 540 treatments per day, while a major recruitment drive will add over 100 nurses and 70 rehabilitation professionals. The strategic partnerships with ENEA Tech and Biomedical are intended to strengthen translational and basic research capabilities to accelerate clinical applications for neurological conditions including stroke, spinal muscular atrophy, multiple sclerosis, and Alzheimer's disease.Pulse 2.0Oversonic Robotics: STMicroelectronics, Fondazione ENEA Tech Biomedical And SpotInvest Acquire Stake In CompanyOversonic Robotics, an Italian cognitive robotics company, announced that STMicroelectronics, Fondazione ENEA Tech Biomedical, and SpotInvest have acquired stakes in the company to support its industrial, technological, and international development. The investment will focus on advancing the company's RoBee cognitive humanoid robot, with applications in manufacturing and healthcare, while strengthening Oversonic's presence in the United States market. The transaction expands the company's shareholder base and provides resources for scaling operations, team growth, and industrial capacity expansion.AijournOversonic Robotics: STMicroelectronics, Fondazione ENEA Tech Biomedical and SpotInvest acquire a stake in the CompanyOversonic Robotics announced that STMicroelectronics, Fondazione ENEA Tech Biomedical, and SpotInvest have acquired stakes in the company to support its industrial, technological, and international growth. The investment will accelerate development of RoBee, the first certified cognitive humanoid robot, and expand applications in manufacturing and healthcare sectors while strengthening the company's presence in the United States. The company aims to position itself among leading deep tech scale-ups in the global cognitive humanoids market.PR NewswireOversonic Robotics: STMicroelectronics, Fondazione ENEA Tech Biomedical and SpotInvest acquire a stake in the CompanySTMicroelectronics, Fondazione ENEA Tech Biomedical, and SpotInvest have acquired stakes in Oversonic Robotics to support the company's industrial, technological, and international growth. The investment will accelerate development of RoBee, the first certified cognitive humanoid robot for industrial and healthcare use, and fund expansion into the United States where Oversonic has offices in Cincinnati and Los Angeles. The transaction strengthens Oversonic's shareholder base alongside existing investors Comat, Datalogic, and AVM SGR, positioning the company to compete in the global cognitive humanoid robotics market.Medical BuyerWISE closes €30M series D financing roundWISE S.p.A., an Italian neurotechnology company, has successfully closed an oversubscribed €30 million Series D financing round, with ENEA Tech and Biomedical joining as a strategic investor alongside existing investors including the European Investment Bank, Wallaby S.p.A., New Frontier S.r.l., Eureka Venture SGR, and Indaco Ventures SGR. The funding will primarily support the clinical development, regulatory certification, and commercial scale-up of WISE's Heron® spinal cord stimulation lead and its broader electrode portfolio. The round also brings leadership changes including the appointment of Laura Iris Ferro as Chairperson and Giuseppe Corvino to the Board of Directors.FinancialContent Business PageWISE Closes Oversubscribed Series D Financing Round of €30 Million, Welcoming ENEA Tech and Biomedical as Strategic New InvestorWISE S.p.A., an Italian medical device company specializing in implantable electrodes for neuromonitoring and neuromodulation, announced the successful closing of an oversubscribed Series D financing round totaling €30 million, with ENEA Tech and Biomedical joining as a strategic investor alongside existing partners. The funding will primarily advance the Heron® lead, WISE's flagship spinal cord stimulation product, through regulatory certification and first-in-human studies, while also supporting commercialization of the WISE Cortical Strip. The round's closing coincides with the appointment of Laura Iris Ferro as Chairperson, strengthening the company's governance as it targets a multi-billion-euro chronic pain treatment market.Startup BusinessFarmaceutica, Wise: Enea tech e Biomerical entra come investitore strategicoWise Spa, an Italian medical device company specializing in advanced implantable electrodes for neuromonitoring and brain-computer interfaces, announced that Enea Tech and Biomedical — a private foundation supervised by Italy's Ministry of Enterprises and Made in Italy and Ministry of Health — has joined as a new strategic investor, bringing its open funding round (launched June 2024) to an oversubscribed final close of 30 million euros. The capital will primarily fund clinical development of the Heron® spinal cord stimulation electrode for chronic pain and the commercial expansion of the Wise Cortical Strip (Wcs®), already carrying MDR, FDA, and TGA certifications. The round also saw the appointment of Laura Iris Ferro as company president and Giuseppe Corvino to the board.StartbaseCellply raises 7.15 million eurosCellply, an Italian biotech, closed a 7.15 million euro financing round led by ENEA Tech e Biomedical. The funds will accelerate international expansion of its VivaCyte AI-based cell analysis platform and development of automated quality controls for cell therapies. The company also added Miro Venturi to its board.BeBeezNel 2025 ben 414,1 mln euro raccolti dalle imprese innovative Life Science. Lo calcola l'Osservatorio LISTUP - BeBeezItalian Life Science innovative firms raised 414.1 million euros in 2025 across 56 rounds, a record. The figure represents 1,591 firms, 11.8% of the total innovative ecosystem, with Biotech/Pharma capturing 91% of capital.GlobeNewswireEurope Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 - Favorable Regulatory Framework Under EMA's Advanced Therapy Medicinal Products (ATMP) PathwayThe Europe cell sheet-based gene therapy market is projected to grow from $219.6 million in 2024 to $926 million by 2035, representing a compound annual growth rate of 13.98%. Foundation ENEA Tech Biomedical emerged as a significant market force following its acquisition of Holostem S.r.l. in December 2023, with Holostem being the first European biotech company focused on epithelial stem cell-based breakthrough medicines including the Holoclar treatment for corneal regeneration. The EMA's Advanced Therapy Medicinal Products framework and public-private partnerships are positioning Europe as a hub for cell sheet-based gene therapy development targeting complex tissue-specific and epithelial disorders.